Sugi Predict

Sugi Predict / Compounds / SCHEMBL1733959

SCHEMBL1733959

SCHEMBL1733959

C=CCOC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.48
▸ RECQL P46063 1/20 0.46
▸ EPHX1 P07099 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ GPR119 Q8TDV5 6/20 0.44
▸ PRMT5 O14744 1/20 0.44
▸ WDR77 Q9BQA1 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ NR1H2 P55055 1/20 0.42
▸ PTPN2 P17706 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PTPN6 P29350 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31279449 0.92 PRMT5 (0.46) HPGDRECQLEPHX1KDM4EMAPT
SCHEMBL18689925 0.92 PRMT5 (0.46) HPGDRECQLEPHX1KDM4EMAPT
SCHEMBL484800 0.87 GPR119 (0.45) HPGDRECQLEPHX1KDM4EMAPT
SCHEMBL1575671 0.87 HPGD (0.49) HPGDRECQLEPHX1KDM4EMAPT
SCHEMBL20128951 0.85 NR1H2 (0.51) HPGDRECQLEPHX1KDM4EMAPT
SCHEMBL5663813 0.84 HPGD (0.47) HPGDRECQLEPHX1KDM4EMAPT
SCHEMBL5663805 0.84 HPGD (0.47) HPGDRECQLEPHX1KDM4EMAPT
SCHEMBL19023078 0.84 HPGD (0.47) HPGDRECQLEPHX1KDM4EMAPT
SCHEMBL20477490 0.83 MEN1 (0.49) HPGDEPHX1MAPTPRMT5WDR77
SCHEMBL8010277 0.83 MEN1 (0.49) HPGDEPHX1MAPTPRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4166557-B1 INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES NOVARTIS AG (CH) 2026-05-06 — — EP disclosed
EP-4722206-A1 BENZO(HETERO)CYCLOALKYL COMPOUNDS FOR ANDROGEN RECEPTOR-DEPENDENT DISEASES Haihe Biopharma Co., Ltd. (CN) 2026-04-08 — — EP disclosed
US-20260042762-A1 MERTK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-02-12 — — US disclosed
EP-4688779-A2 NOVEL COMPOUNDS AND USES THEREOF Acelink Therapeutics, Inc. (US) 2026-02-11 — — EP disclosed
US-12441733-B2 Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors NOVARTIS AG (CH) 2025-10-14 — — US disclosed
CN-119836420-A 2-Indolone compounds as VEGFR and PKa dual-target inhibitors, preparation method and application thereof 远森制药（杭州）有限公司 2025-04-15 — — CN disclosed
WO-2025007853-A1 2-INDOLINONE COMPOUND SERVING AS VEGFR AND PKA DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 远森制药（杭州）有限公司 2025-01-09 — — WO disclosed
WO-2024245408-A1 BENZO(HETERO)CYCLOALKYL COMPOUNDS FOR ANDROGEN RECEPTOR-DEPENDENT DISEASES 上海海和药物研究开发股份有限公司 2024-12-05 — — WO disclosed
EP-4467549-A2 INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES Novartis AG (CH) 2024-11-27 — — EP disclosed
WO-2024211244-A2 NOVEL COMPOUNDS AND USES THEREOF ACELINK THERAPEUTICS, INC. (US) 2024-10-10 — — WO disclosed
EP-1432420-A2 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS Acadia Pharmaceuticals Inc. (US) 2004-06-30 — — EP disclosed
US-20040067931-A1 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. 2004-04-08 — — US disclosed
US-20030100545-A1 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS, INC. 2003-05-29 — — US disclosed
WO-2003028650-A2 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS, INC. (US) 2003-04-10 — — WO disclosed
EP-1173472-A1 CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-23 — — EP disclosed
WO-2000064927-A1 CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 — — WO disclosed
US-5648368-A ANTICOAGULANTS MERCK & CO., INC. (US) 1997-07-15 — — US disclosed
EP-0673247-A4 FIBRINOGEN RECEPTOR ANTAGONISTS. MERCK & CO INC (US) 1996-05-01 — — EP disclosed
EP-0673247-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1995-09-27 — — EP disclosed
WO-1994012181-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1994-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100545-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM5, CHRM1 HPGD 2776/4885RECQL 4337/4885EPHX1 2109/4885
US-20260042762-A1 MERTK DEGRADERS AND USES THEREOF MERTK, CRKL, OSTC HPGD 3405/4885RECQL 4021/4885EPHX1 1971/4885
US-20040067931-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM5, CHRM1 HPGD 2776/4885RECQL 4337/4885EPHX1 2109/4885
US-12441733-B2 Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors BTK, ABL1, LYN HPGD 3427/4885RECQL 606/4885EPHX1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.